
    
      Test groups: 2 (120 subjects/group). 1 group receiving GSK Biologicals' 10-valent
      pneumococcal conjugate vaccine + DTPa combined vaccine; Control group receiving GSK
      Biologicals' Havrix + DTPa combined vaccine
    
  